Conversion of non-neuronal cells to neurons is a promising potential strategy for the treatment of neurodegenerative diseases. Recent studies have reported that shRNA-, CasRx-, or ASO-mediated Ptbp1 suppression could reprogram resident astrocytes to neurons. However, some groups have disputed the data interpretation of the reported neuron conversion events. These controversies surrounding neuron conversion may due to differences in the astrocyte fate-mapping systems. Here, we suppressed Ptbp1 using Cas13X, and labeled astrocytes with the HA tag fused to Cas13X (Cas13X-NLS-HA). Compared with the GFAP-driven tdTomato labeling system (AAV-GFAP::tdTomato-WPRE) in previous studies, we found no astrocyte-to-neuron conversion in mouse striatum via the HA-tagged labeling system. Our ndings indicate Ptbp1 knockdown failed to induce neuron conversion in vivo.
Full TextConversion of non-neuronal cells to neurons is a promising potential strategy for the treatment of neurodegenerative diseases. Recent studies have reported that shRNA-, CasRx-, or ASO-mediated Ptbp1 suppression could reprogram resident astrocytes to neurons 1-3 . However, some groups have disputed the data interpretation of the reported neuron conversion events 4-8 . These controversies surrounding neuron conversion may due to differences in the astrocyte fate-mapping systems. Here, we suppressed Ptbp1 using Cas13X, and labeled astrocytes with the HA tag fused to Cas13X (Cas13X-NLS-HA). Compared with the GFAP-driven tdTomato labeling system (AAV-GFAP::tdTomato-WPRE) in previous studies, we found no astrocyte-to-neuron conversion in mouse striatum via the HA-tagged labeling system. Our ndings indicate Ptbp1 knockdown failed to induce neuron conversion in vivo.Previously, we found that CasRx could repress Ptbp1 in astrocytes and induce astrocyte-to-neuron (AtN) conversion 2 . However, technical di culties in the CasRx-mediated Ptbp1 knockdown reported by other groups 5,8 led us to investigate alternative approaches to repress Ptbp1. To this end, we tested the e ciency of Ptbp1 knockdown by Cas13X, a hyper-compact CRISPR-Cas13 protein with low collateral effect recently identi ed by our group 9 . We screened ve sgRNAs targeting Ptbp1 mRNA (Fig. 1A) and found that sgRNAs-2, -3, and − 5, independently or combined, could effectively knock down Ptbp1 expression in HEK293T, Cos7, and N2a cell lines (Fig. 1B).To estimate whether Ptbp1 could be knocked down by Cas13X in vivo, we applied an 1.5E9 vg/injection of AAV-PHP.eB capsid with a 681 bp-length human GFAP promoter 10 to drive astrocyte-speci c expression of Cas13X-NLS-HA-sgPtbp1-(2,3,5) or the non-target control (sgNT) in C57BL/6 mice (Fig. 1C, 1D). Immuno uorescent staining of brain sections showed that although the endogenous mouse GFAP signal was unable to maintain for 2 months (Fig. 1E), the Cas13X-HA signal persistently over-expressed (Fig. 1F), and the PTBP1 signal signi cantly decreased over time (Fig. 1D, 1G), which was indicated by the decreasing proportion of Ptbp1 + HA + GFAP